A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants

Pooled Human Plasma from Innovative Research was used in the following study:

A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants

Ryan P. Trombetta, Paul M. Dunman, Edward M. Schwarz, Stephen L. Kates, Hani A. Awad

American Society for Microbiology
October 2018, mSphere open-acces article

"... Briefly, overnight cultures of UAMS-1 were adjusted to ∼1 × 10^6 CFU/ml in TSB supplemented with 10% (vol/vol) pooled human plasma (Innovative Research, Novi, MI) and added to individual wells of MBEC plates at a volume of 150 µl. Plates were incubated for 24 h at 37°C with shaking at 110 rpm. After incubation, peg lids were transferred to a 96-well microtiter plate containing 200 µl of PBS and washed for 1 min with shaking at 110 rpm. Then washed peg lids were transferred to an antimicrobial challenge plate containing 2-fold serial dilutions of 200 µl of gentamicin and validated HTS drugs in TSB. The challenged biofilm was incubated for an additional 24 h at 37°C with shaking at 110 rpm ..."

Related products available from Innovative Research also include:

• Single Donor Human Plasma Whole Blood Derived
• Pooled Human Serum Off The Clot
• Single Donor Human Serum Off The Clot
• Single Donor Human Whole Blood